Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 déc. 2025 08h00 HE | Source: CoRegen, Inc.

CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors

HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of solid tumor cancer,...
10 sept. 2025 08h00 HE | Source: CoRegen, Inc.

CoRegen, Inc. Strengthens Leadership Team with the Appointments of Sonja Nelson as Chief Financial Officer and Peter Gelinas as Chief Technical Officer

HOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced...
31 juil. 2025 09h06 HE | Source: CoRegen, Inc.

CoRegen, Inc. Appoints Biotech Veteran Sonal Gupta, M.D., Ph.D., as Chief Medical Officer

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced the...
09 juil. 2025 08h00 HE | Source: CoRegen, Inc.

CoRegen, Inc. Closes More Than $93 Million Financing

HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced...
16 nov. 2023 10h17 HE | Source: CoRegen, Inc.

CoRegen Appoints Edward J. Benz, M.D., to its Board of Directors

HOUSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, announced today the...
01 juin 2023 10h17 HE | Source: CoRegen, Inc.

CoRegen Inc. Announces Publication of Preclinical Research Demonstrating Treatment with Modified Tregs Eliminates Tumors and Prevents Recurrence Without Side Effects

HOUSTON, June 01, 2023 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer and chronic diseases,...